On March 26, Ge Longhui | Maibo Pharmaceutical-B (02181.HK) announced that for the year ended December 31, 2023, the Group's revenue increased 55.9% year-on-year to RMB 87.161 million, mainly due to a sharp increase in drug sales revenue during the reporting period compared to last year. Losses attributable to company owners were approximately RMB 209 million, while losses attributable to company owners during the same period last year were approximately RMB 211 million, with a basic loss of RMB 0.05 per share.
迈博药业-B(02181.HK)：2023年净亏损2.09亿元
Maibo Pharmaceutical-B (02181.HK): net loss of 209 million yuan in 2023
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.